Ardizzoni, Andrea

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/ neu –Positive Metastatic Breast Cancer

Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 981

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F. V., Schiller, J. H., Paesmans, M., Radosavljevic, D., Paccagnella, A., Zatloukal, P., Mazzanti, P., et al. (2007) · JNCI Journal of the National Cancer Institute

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 612

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Soria, J.-C., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., Göker, E., Georgoulias, V., Li, W., Isla, D., et al. (2015) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 433

Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance

Raschi, E., Gatti, M., Gelsomino, F., Ardizzoni, A., Poluzzi, E., & De Ponti, F. (2020) · Targeted Oncology

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 157

Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials

Rizzo, A., Mollica, V., Santoni, M., Ricci, A. D., Rosellini, M., Marchetti, A., Montironi, R., Ardizzoni, A., & Massari, F. (2022) · European Urology Focus

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 91

PTEN status in advanced colorectal cancer treated with cetuximab

Negri, F. V., Bozzetti, C., Lagrasta, C. A., Crafa, P., Bonasoni, M. P., Camisa, R., Pedrazzi, G., & Ardizzoni, A. (2010) · British Journal of Cancer

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 83

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial

Goss, G. D., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., Göker, E., Georgoulias, V., Li, W., Guclu, S., et al. (2018) · JAMA Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 55

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

Cavazzoni, A., Alfieri, R. R., Cretella, D., Saccani, F., Ampollini, L., Galetti, M., Quaini, F., Graiani, G., Madeddu, D., Mozzoni, P., et al. (2012) · Molecular Cancer

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 44

The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System

Raschi, E., Fusaroli, M., Massari, F., Mollica, V., Repaci, A., Ardizzoni, A., Poluzzi, E., Pagotto, U., & Di Dalmazi, G. (2022) · The Journal of Clinical Endocrinology & Metabolism

Pharmacovigilance and Adverse Drug ReactionsAdrenal Hormones and Disorders

Cited by 17